Laura Else

Cancer statistics, 2020

Cancer statistics, 2019

Cancer Statistics, 2021

Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy

HIV-1 persistence in the central nervous system: viral and host determinants during antiretroviral therapy

Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study

Microglial cell origin and phenotypes in health and disease

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy

HIV, Antiretroviral Therapies, and the Brain

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

Switching from twice‐daily abacavir and lamivudine to the once‐daily fixed‐dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy

Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

<p>Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics</p>

A computational approach for predicting off-target toxicity of antiviral ribonucleoside analogues to mitochondrial RNA polymerase

Advancements in nano-enabled therapeutics for neuroHIV management

Antiviral drug discovery: broad-spectrum drugs from nature

Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?

U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

Interventions for enhancing medication adherence

New Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development

Natural Products as Sources of New Drugs from 1981 to 2014

Rational Design of Doravirine: From Bench to Patients

Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia

The importance of drug–drug interactions in the DAA era

A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients

Efavirenz‐ but not nevirapine‐based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub‐dermal contraceptive implant

Validation of a rapid and sensitive high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds

Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract

Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study

Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation

Abacavir Plasma Pharmacokinetics in the Absence and Presence of Atazanavir/Ritonavir or Lopinavir/Ritonavir and Vice Versa in HIV-Infected Patients